BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 33190932)

  • 1. Testing for lynch syndrome in people with endometrial cancer using immunohistochemistry and microsatellite instability-based testing strategies - A systematic review of test accuracy.
    Stinton C; Fraser H; Al-Khudairy L; Court R; Jordan M; Grammatopoulos D; Taylor-Phillips S
    Gynecol Oncol; 2021 Jan; 160(1):148-160. PubMed ID: 33190932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.
    Stinton C; Jordan M; Fraser H; Auguste P; Court R; Al-Khudairy L; Madan J; Grammatopoulos D; Taylor-Phillips S
    Health Technol Assess; 2021 Jun; 25(42):1-216. PubMed ID: 34169821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
    Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
    Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
    Kahn RM; Gordhandas S; Maddy BP; Baltich Nelson B; Askin G; Christos PJ; Caputo TA; Chapman-Davis E; Holcomb K; Frey MK
    Cancer; 2019 Sep; 125(18):3172-3183. PubMed ID: 31150123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequences of universal MSI/IHC in screening ENDOMETRIAL cancer patients for Lynch syndrome.
    Batte BA; Bruegl AS; Daniels MS; Ring KL; Dempsey KM; Djordjevic B; Luthra R; Fellman BM; Lu KH; Broaddus RR
    Gynecol Oncol; 2014 Aug; 134(2):319-25. PubMed ID: 24933100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.
    Goodfellow PJ; Billingsley CC; Lankes HA; Ali S; Cohn DE; Broaddus RJ; Ramirez N; Pritchard CC; Hampel H; Chassen AS; Simmons LV; Schmidt AP; Gao F; Brinton LA; Backes F; Landrum LM; Geller MA; DiSilvestro PA; Pearl ML; Lele SB; Powell MA; Zaino RJ; Mutch D
    J Clin Oncol; 2015 Dec; 33(36):4301-8. PubMed ID: 26552419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPM2AIP1 Immunohistochemistry Can Be Used as Surrogate Testing for MLH1 Promoter Methylation in Endometrial Cancer.
    Mrkonjic M; Turashvili G
    Am J Surg Pathol; 2022 Mar; 46(3):376-382. PubMed ID: 34772843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients.
    Hampel H; Frankel W; Panescu J; Lockman J; Sotamaa K; Fix D; Comeras I; La Jeunesse J; Nakagawa H; Westman JA; Prior TW; Clendenning M; Penzone P; Lombardi J; Dunn P; Cohn DE; Copeland L; Eaton L; Fowler J; Lewandowski G; Vaccarello L; Bell J; Reid G; de la Chapelle A
    Cancer Res; 2006 Aug; 66(15):7810-7. PubMed ID: 16885385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical staining for p16 and BRAFV600E is useful to distinguish between sporadic and hereditary (Lynch syndrome-related) microsatellite instable colorectal carcinomas.
    Boissière-Michot F; Frugier H; Ho-Pun-Cheung A; Lopez-Crapez E; Duffour J; Bibeau F
    Virchows Arch; 2016 Aug; 469(2):135-44. PubMed ID: 27220764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review.
    Yokoyama T; Takehara K; Sugimoto N; Kaneko K; Fujimoto E; Okazawa-Sakai M; Okame S; Shiroyama Y; Yokoyama T; Teramoto N; Ohsumi S; Saito S; Imai K; Sugano K
    BMC Cancer; 2018 May; 18(1):576. PubMed ID: 29783979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficient molecular screening of Lynch syndrome by specific 3' promoter methylation of the MLH1 or BRAF mutation in colorectal cancer with high-frequency microsatellite instability.
    Nakagawa H; Nagasaka T; Cullings HM; Notohara K; Hoshijima N; Young J; Lynch HT; Tanaka N; Matsubara N
    Oncol Rep; 2009 Jun; 21(6):1577-83. PubMed ID: 19424639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of HNPCC by molecular analysis of colorectal and endometrial tumors.
    Vasen HF; Hendriks Y; de Jong AE; van Puijenbroek M; Tops C; Bröcker-Vriends AH; Wijnen JT; Morreau H
    Dis Markers; 2004; 20(4-5):207-13. PubMed ID: 15528786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Screening With Combined Age- and Morphology-Based Criteria Enriches Detection of Lynch Syndrome in Endometrial Cancer.
    Lin DI; Hecht JL
    Int J Surg Pathol; 2016 Jun; 24(4):297-305. PubMed ID: 26842347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of test accuracy studies evaluating molecular micro-satellite instability testing for the detection of individuals with lynch syndrome.
    Coelho H; Jones-Hughes T; Snowsill T; Briscoe S; Huxley N; Frayling IM; Hyde C
    BMC Cancer; 2017 Dec; 17(1):836. PubMed ID: 29221446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of tumor testing for lynch syndrome in endometrial cancers at a large academic medical center.
    Moline J; Mahdi H; Yang B; Biscotti C; Roma AA; Heald B; Rose PG; Michener C; Eng C
    Gynecol Oncol; 2013 Jul; 130(1):121-6. PubMed ID: 23612316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of reflex testing for Lynch syndrome in women with endometrial cancer in the UK setting.
    Snowsill TM; Ryan NAJ; Crosbie EJ; Frayling IM; Evans DG; Hyde CJ
    PLoS One; 2019; 14(8):e0221419. PubMed ID: 31469860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.
    Rabban JT; Calkins SM; Karnezis AN; Grenert JP; Blanco A; Crawford B; Chen LM
    Am J Surg Pathol; 2014 Jun; 38(6):793-800. PubMed ID: 24503759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One size may not fit all: the debate of universal tumor testing for Lynch syndrome.
    Lu KH; Ring KL
    Gynecol Oncol; 2015 Apr; 137(1):2-3. PubMed ID: 25818039
    [No Abstract]   [Full Text] [Related]  

  • 20. The prevalence of Lynch syndrome in women with endometrial cancer: a systematic review protocol.
    Ryan NAJ; Blake D; Cabrera-Dandy M; Glaire MA; Evans DG; Crosbie EJ
    Syst Rev; 2018 Aug; 7(1):121. PubMed ID: 30115102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.